Abogen Biosciences is a fully integrated new powerhouse in the evolving field of mRNA-based therapeutics. Driven by the mission to revolutionize the future of health and life, we are committed to pioneering mRNA medicine through innovation, integration and insight.
Founded in 2019, we have been rapidly rising to prominence in biotechnology powered by our proprietary clinically validated mRNA-LNP platform that combines advanced AI technologies, automation and scalable manufacturing. With deep expertise in mRNA modifications and delivery, we are pushing the boundaries of immuno-oncology, protein replacement therapies and infectious disease treatments.
At the crossroads of science, technology and healthcare, we aspire to deliver transformative medicines through mRNA innovations, turning the impossible into reality.
-
AccountableWe dedicate ourselves to patients. With the mission to deliver transformative medicines through scientific innovations, we encourage everyone to be a true leader with integrity, urgency, and a strong commitment to timelines and results.
-
BoldWe relentlessly focus on finding meaningful breakthroughs and transformative solutions to otherwise untreatable diseases. We strive to challenge norms, seek truth with facts and data, and innovate fearlessly for an ultimate answer through trial and error.
-
Open-mindedThere is no permanent authority in scientific research. By advocating openness and diversity, we create an inclusive workplace where talents are respected, different ideas are heard, and curiosity is cherished. We learn from one another and bring out the best in each other.
-
The human body has incredible potentials, and it just needs the right message of what proteins to synthesize to fight against diseases. As we further advance our technology platform, we believe mRNA will completely transform the way how medicines are made and how diseases are treated.—— Bo Ying, Ph D, Founder, Chairman and CEO
Bo Ying, Ph.D.Founder, Chairman and CEODr. Bo Ying has dedicated over a decade of his career to the technology research into nucleic acid -based therapeutics and the development of transformative drugs. He founded Abogen, a biotechnology company with a mission of curing otherwise untreatable diseases through mRNA science and technology.
As the founder, Dr Ying also has served as Chairman of the board and CEO of Abogen. Under his leadership, the company has established its own proprietary mRNA platform and delivery technology that allowed the development of the therapeutics and vaccines for infectious diseases, cancer, and rare diseases. Most recently, Abogen’s mRNA platform capabilities have come together to allow the authorized use and approval of first China made mRNA vaccine against the COVID-19 pandemic.
Prior to founding Abogen, Dr Ying had held several roles at numerous leading biopharmaceutical and biotechnologies companies in the US, mainly responsible for leading drug formulation, process development, technology transfer and manufacturing. Across his career, he takes pride in a broad array of innovative drug developing experiences in siRNA, mRNA-based therapies for tumor immunotherapy、cancer vaccines and gene-editing drug product candidates.
Dr. Ying received his bachelor’s degree in life sciences from Fudan University, Shanghai, and Ph.D. in pharmaceutical sciences from Northeastern University. He is credited as the inventor of a dozen issued patents and patent applications, and his work appears in journals such as Cell and Lancet.
Over the years, Dr. Ying has held several positions in influential organizations. From 2018 to 2019, he served as the president of the Chinese-American BioMedical Association (CABA) in Boston, where he made contributions to the advancement of science and technological innovation with great potential to improve human health.